DNMT1 and myelodysplastic syndrome: Currently, two DNMT inhibitors (DNMTi), the nucleoside analogues azacitydine (5-AZA) and decitabine (5-AZA-CdR), have been approved by FDA and the European Medicines Agency (EMA) against myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML), and chronic myelomonocytic leukaemia (CMML).